Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.07.2023 | Case report

Nivolumab

Lack of efficacy: 5 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Forschner A, et al. Circulating tumor DNA (ctDNA) in the detection of relapse in melanoma patients with adjuvant anti-PD-1 therapy. Journal der Deutschen Dermatologischen Gesellschaft 20: 867-871, No. 6, Jun 2022. Available from: URL: http://dx.doi.org/10.1111/ddg.14766 Forschner A, et al. Circulating tumor DNA (ctDNA) in the detection of relapse in melanoma patients with adjuvant anti-PD-1 therapy. Journal der Deutschen Dermatologischen Gesellschaft 20: 867-871, No. 6, Jun 2022. Available from: URL: http://​dx.​doi.​org/​10.​1111/​ddg.​14766
Metadaten
Titel
Nivolumab
Lack of efficacy: 5 case reports
Publikationsdatum
01.07.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-42482-0

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Atorvastatin

Case report

Dexamethasone

Case report

Multiple drugs

Case report

Methotrexate

Case report

Chlordiazepoxide